Find Psychiatry/Psychology Drugs in Phase I Clinical Development in UNITED STATES

Lead Product(s): CVL-936

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of CVL-936 in healthy volunteers ages 18 to 50.

Lead Product(s): Ibogaine Hydrochloride

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: ATAI Life Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Investment January 24, 2020

Details:

The investment aims at developing treatment protocol for safety of patients who are taking ibogaine for treatment of opioid use disorder (OUD).

Lead Product(s): Etifoxine

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 19, 2020

Details:

Data from this study could provide important insights for a broad range of neurological disorders beyond anxiety and depression.